Have a question?
Please get in touch with our team in case of any queries
THE GLOBAL MULTIMODAL IMAGING MARKET SIZE IS EXPECTED TO REACH USD 5.49 BILLION BY 2029 FROM USD 4.02 BILLION IN 2023, GROWING AT A CAGR OF 5.35% DURING THE FORECAST PERIOD.
The Multimodal Imaging Market Size, Share, & Trends Analysis Report By
- Technology: PET/CT, PET/MR, SPECT/CT, OCT/FMT, and Others
- Application: Diagnostic & Clinical (Brain & Neurology, Oncology, Cardiology, Ophthalmology, and Others) and Research
- End-user: Hospitals, Diagnostic Imaging Centers, Academic & Research Centers, and Others
- Geography: North America, Europe, APAC, Latin America, and Middle East & Africa
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029.
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
MULTIMODAL IMAGING MARKET REPORT SCOPE
REPORT ATTRIBUTE | DETAILS |
---|---|
Market Size (2029) | USD 5.49 Billion |
Market Size (2023) | USD 4.02 Billion |
CAGR (2023-2029) | 5.35% |
HISTORIC YEAR | 2020-2022 |
BASE YEAR | 2023 |
FORECAST YEAR | 2024-2029 |
SEGMENTS BY | Technology, Application, End-user, Geography |
GEOGRAPHIC ANALYSIS | North America, Europe, APAC, Latin America, and Middle East & Africa |
KEY PLAYERS | Canon Medical Systems, GE Healthcare, Koninklijke Philips, Shimadzu Corporation, and Siemens Healthineers |
MARKET OVERVIEW
The global multimodal imaging market was valued at USD 4.02 billion in 2023 and is expected to reach USD 5.49 billion by 2029, growing at a CAGR of 5.35% during the forecast period. In medical diagnostics, multimodal imaging has emerged as a powerful tool, revolutionizing how healthcare providers visualize and understand various physiological processes within the human body. Several key factors fuel the global multimodal imaging market. Firstly, the increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions necessitates advanced imaging techniques for accurate diagnosis and treatment planning. Additionally, technological advancements in imaging modalities, such as integrating multiple imaging techniques into a single platform, have expanded the capabilities of multimodal imaging systems. Furthermore, the growing demand for minimally invasive procedures and personalized medicine has heightened the need for precise and comprehensive diagnostic imaging solutions, driving multimodal imaging market growth.
Multimodal imaging combines two or more imaging modalities, such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), single-photon emission computed tomography (SPECT), ultrasound, and optical imaging, to provide complementary information and enhance diagnostic accuracy. For example, PET/CT combines the metabolic information obtained from PET with the anatomical details provided by CT, enabling the detecting and localizing of abnormalities with high sensitivity and specificity.
Multimodal imaging applications span various medical specialties, including oncology, cardiology, neurology, orthopedics, and ophthalmology. In oncology, multimodal imaging is crucial in cancer staging, treatment response assessment, and surveillance. In cardiology, it facilitates the evaluation of myocardial perfusion, viability, and function, aiding in the diagnosis and management of cardiovascular diseases. In neurology, multimodal imaging enables the localization of brain lesions, characterization of neurodegenerative disorders, and evaluation of cerebral blood flow and metabolism. Moreover, multimodal imaging has applications in intraoperative guidance, image-guided interventions, and preclinical research.
The future of the global multimodal imaging market looks promising, driven by ongoing technological innovations, strategic collaborations between industry stakeholders, and increasing investments in research and development. Artificial intelligence and machine learning are expected to enhance the capabilities of multimodal imaging systems, enabling automated image analysis, personalized treatment planning, and predictive modeling. Moreover, the integration of novel imaging probes and contrast agents, along with the development of portable and affordable imaging devices, holds immense potential for expanding the reach of multimodal imaging to underserved populations and remote regions.
Overall, the global multimodal imaging market is poised for significant growth, driven by the increasing demand for precise diagnostic solutions, advancements in imaging technologies, and expanding applications across various medical specialties. While facing challenges related to cost, accessibility, and data integration, multimodal imaging holds promise for revolutionizing healthcare delivery, improving patient outcomes, and advancing medical research in the years to come.
MARKET TRENDS & DRIVERS
Growing Adoption of AI & Analytics in Diagnostic Imaging
The growing adoption of AI and analytics in diagnostic imaging undoubtedly creates exciting opportunities for the multimodal imaging market. By unlocking the power of complex data, AI has the potential to transform the way we diagnose and treat diseases, leading to improved patient outcomes and a more efficient healthcare system. However, navigating the ethical and regulatory landscape alongside ensuring responsible development will be critical in realizing the full potential of this transformative technology.
Multimodal Molecular Imaging in Drug Discovery and Development
The quest for faster, more efficient, and personalized drug development has led to the emergence of exciting new technologies. Among these, multimodal molecular imaging stands out as a game-changer, revolutionizing the way of visualizing and understanding diseases, ultimately shaping the future of pharmaceutical innovation, and paving the way for a booming multimodal imaging market. Multimodal imaging overcomes this limitation by seamlessly integrating data from multiple imaging modalities, such as PET, MRI, CT, and ultrasound, into a comprehensive picture.
Growing Geriatric Population & Subsequent Rise in Chronic Conditions
Multimodal imaging, the synergistic combination of two or more imaging modalities like PET, MRI, and CT, offers a multifaceted solution to the diagnostic challenges posed by chronic diseases in aging populations. Each modality provides a unique perspective, revealing anatomical structures and functional processes. The growing need for advanced diagnostics in the face of rising chronic disease prevalence among older adults propels the multimodal imaging market forward. Industry analysts anticipate a significant rise in market value.
Technological Advancements in Diagnostics Imaging Modalities
The healthcare landscape is witnessing a pivotal shift towards personalized medicine, demanding ever-more accurate and comprehensive diagnostic tools. The scope of multimodal imaging is where technological advancements in individual imaging modalities are shaping their markets and fueling the explosive growth of a combined force. Integrated scanners combining two or more modalities, like PET/CT or PET/MRI, offer one-stop solutions, streamlining workflows and reducing patient discomfort. Combining information from various modalities gives clinicians a more comprehensive view of disease, leading to earlier and more accurate diagnoses and ultimately improving patient outcomes.
Recent Developments & Partnerships in the Multimodal Imaging Industry
The multimodal imaging market, fueled by the convergence of diverse imaging modalities, is undergoing a period of rapid evolution. Recent developments and strategic partnerships are pushing the boundaries of technology and propelling the market toward wider adoption and impactful applications. Collaborations between pharmaceutical and imaging companies accelerate drug development by utilizing multimodal imaging for early disease detection, target validation, and therapy monitoring. Research institutions and industry players collaborate to translate innovative imaging technologies into clinical practice.
SEGMENTATION INSIGHTS
INSIGHTS BY TECHNOLOGY
The global multimodal imaging market is segmented based on technology into PET/CT, PET/MR, SPECT/CT, OCT/FMT, and others. The PET/CT accounted for the largest market in 2023. PET utilizes radiopharmaceuticals to detect metabolic activity within tissues, aiding in diagnosing and staging cancers, neurological disorders, and cardiovascular diseases. CT offers detailed anatomical information, facilitating the localization and characterization of abnormalities detected on PET scans. PET/CT is widely used in oncology for tumor detection, staging, treatment planning, and response assessment, as well as in cardiology and neurology.
PET/MR offers advantages over PET/CT, including improved soft tissue contrast, reduced radiation exposure, and potential synergistic effects between PET and MRI. PET/MR is utilized in oncology, neurology, and cardiology for applications such as tumor imaging, neurodegenerative disease assessment, and myocardial perfusion imaging. SPECT/CT integrates the functional imaging capabilities of SPECT with the anatomical imaging provided by CT. SPECT/CT is used in nuclear medicine for myocardial perfusion imaging, bone scans, thyroid imaging, and oncological applications. OCT/FMT is applied in ophthalmology for retinal imaging and angiography and in oncology for preclinical research and drug development.
INSIGHTS BY APPLICATION
The global multimodal imaging market encompasses various diagnostic and clinical applications and applications in biomedical research. From brain & neurology and cardiology to oncology, ophthalmology, obstetrics and gynecology, and beyond, multimodal imaging is pivotal in advancing medical diagnostics, treatment planning, and research across various medical specialties.
Multimodal imaging techniques such as MRI, CT, PET, SPECT, and fMRI are used for the diagnosis and treatment planning of neurological disorders such as stroke, brain tumors, epilepsy, and neurodegenerative diseases. Techniques such as MRI, CT, ultrasound, and molecular imaging are also utilized to assess tumor microstructure, vascularity, and metabolism, guiding personalized treatment approaches and monitoring disease progression. In cardiology, multimodal imaging assesses cardiac structure, function, perfusion, and viability. Techniques such as PET/CT, PET/MRI, echocardiography, cardiac MRI, and coronary CT angiography are utilized to diagnose and manage cardiovascular diseases, including coronary artery disease, heart failure, valvular disorders, and cardiomyopathies.
In ophthalmology, multimodal imaging techniques such as optical coherence tomography (OCT), fundus photography, fluorescein angiography, and ultrasound biomicroscopy are used for the diagnosis and management of retinal disorders, including age-related macular degeneration, diabetic retinopathy, glaucoma, and retinal vascular diseases. Further, multimodal imaging techniques are widely used in biomedical research to study physiological processes, disease mechanisms, and therapeutic interventions. Researchers utilize multimodal imaging to investigate molecular pathways, cellular interactions, and tissue responses in preclinical and translational studies. Multimodal imaging plays a crucial role in drug development and pharmacological research by providing non-invasive methods for evaluating drug efficacy, pharmacokinetics, and biodistribution. Researchers utilize multimodal imaging to assess drug-target interactions, monitor therapeutic responses, and optimize treatment regimens in preclinical and clinical trials. Researchers utilize multimodal imaging to assess tumor microenvironment, angiogenesis, and therapeutic response, guiding the development of novel anticancer therapies and personalized treatment approaches.
INSIGHTS BY END-USER
The global multimodal imaging market encompasses various end-users spanning hospitals, diagnostic imaging centers, research institutions, and others. Each end-user segment contributes uniquely to the growth and evolution of the market, fueling demand for advanced multimodal imaging technologies and applications across different medical diagnostics and research domains.
Hospitals represent the largest end-user segment in the global multimodal imaging market. These facilities utilize multimodal imaging systems for diagnostic and therapeutic applications across various medical specialties, including radiology, neurology, cardiology, oncology, ophthalmology, and orthopedics. Diagnostic imaging centers are specialized facilities that provide various imaging services to patients referred by healthcare providers. These centers offer advanced multimodal imaging techniques such as MRI, CT, PET, SPECT, ultrasound, and nuclear medicine imaging. Diagnostic imaging centers are vital in early disease detection, screening, and monitoring, serving as important end-users in the multimodal imaging market.
Research institutes and academic centers contribute significantly to advancing multimodal imaging technologies through research, development, and clinical trials. These institutions utilize multimodal imaging systems for preclinical and clinical studies to elucidate disease mechanisms, evaluate novel imaging agents, and assess treatment responses. Biopharmaceutical companies leverage multimodal imaging technologies to support drug discovery, development, and clinical trials. Multimodal imaging is crucial in preclinical research by providing non-invasive imaging biomarkers for evaluating drug efficacy, pharmacokinetics, and biodistribution.
GEOGRAPHICAL ANALYSIS
North America, particularly the US and Canada, dominates the global multimodal imaging market due to well-established healthcare infrastructure, high healthcare spending, and early adoption of advanced medical technologies. The presence of major multinational healthcare companies, research institutions, and academic centers drives innovation and market growth in this region. The demand for multimodal imaging in the region is fueled by the prevalence of chronic diseases, the aging population, an increasing emphasis on early disease detection, and personalized medicine.
Europe is a significant market for multimodal imaging technologies, with countries like Germany, the UK, France, Italy, Spain, Russia, and the Netherlands leading the way. The region benefits from robust healthcare systems, government investments in healthcare infrastructure, and collaborations between academia and industry. The Asia-Pacific region, including countries like China, Japan, India, South Korea, and Australia, represents a rapidly growing multimodal imaging market. Increasing healthcare expenditure, expanding medical tourism, and rising prevalence of chronic diseases drive market growth in the APAC region.
Latin America is an emerging multimodal imaging market, with countries like Brazil, Mexico, Argentina, and Colombia witnessing growing demand for advanced medical imaging technologies. Market growth is driven by improving healthcare infrastructure, rising disposable income, and increasing awareness about early disease detection and treatment benefits. The Middle East & Africa region, including countries like Turkey, Saudi Arabia, and South Africa, UAE presents opportunities for multimodal imaging market growth. Increasing healthcare investments, the expanding private healthcare sector, and the rising prevalence of chronic diseases drive demand for advanced medical imaging technologies.
COMPETITIVE LANDSCAPE
The global multimodal imaging market is a dynamic and fiercely competitive landscape driven by technological advancements, increasing demand for precise diagnostic solutions, and a growing emphasis on personalized healthcare. The global multimodal imaging market is dominated by several key players, each with a significant industry presence and a diverse portfolio of imaging solutions. Some of the leading players in the market include Canon Medical Systems, GE Healthcare, Koninklijke Philips, Siemens Healthineers, and Shimadzu Corporation. Furthermore, leading players invest heavily in research and development to drive innovation in multimodal imaging technologies. This includes developing advanced imaging systems with enhanced capabilities such as AI-driven image analysis, real-time image fusion, and 3D/4D imaging.
The global multimodal imaging market is expected to grow continuously, driven by technological innovations, strategic partnerships, and increasing demand for precision diagnostic solutions. AI-driven imaging solutions, portable imaging devices, and the integration of multimodal imaging with molecular imaging techniques are expected to shape the future landscape of the market. Canon Medical Systems is a prominent player in the multimodal imaging market, offering various advanced medical imaging solutions. Focusing on innovation and cutting-edge technology, the company provides comprehensive imaging systems catering to various medical specialties, including radiology, cardiology, oncology, and neurology. The company has introduced state-of-the-art imaging systems incorporating artificial intelligence (AI) algorithms for improved diagnostic accuracy and efficiency.
Frequently Asked Questions
How big is the global multimodal imaging market?
What is the growth rate of the global multimodal imaging market?
Which region dominates the global multimodal imaging market share?
What are the significant trends in the global multimodal imaging market?
Who are the key players in the global multimodal imaging market?
The global multimodal imaging market size is expected to grow at a CAGR of approximately 5.35% from 2023 to 2029.
The following factors are likely to contribute to the growth of the global multimodal imaging market during the forecast period:
- Growing Geriatric Population & Subsequent Rise in Chronic Conditions
- Technological Advancements in Diagnostics Imaging Modalities
- Recent Developments & Partnerships In the Multimodal Imaging Market
- Non-invasive Imaging Fueling Growth in Neuroscience & Oncology Application
Base Year: 2023
Forecast Year: 2024-2029
The report considers the present scenario of the global multimodal imaging market and its market dynamics for 2024−2029. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry.
Key Company Profiles
- Canon Medical Systems
- Business Overview
- Product Offerings
- Key Strategies
- Key Strengths
- Key Opportunities
- GE Healthcare
- Koninklijke Philips
- Shimadzu Corporation
- Siemens Healthineers
Other Prominent Vendors
- Bruker
- Business Overview
- Product Offerings
- Mediso
- MILabs B.V.
- MinFound Medical Systems
- MR Solution
- Shanghai United Imaging Healthcare
- SOFIE
- Spectrum Dynamics Medical
- Topcon
Segmentation by Technology
Segmentation by Application
- Diagnostic & Clinical
- Brain & Neurology
- Oncology
- Cardiology
- Ophthalmology
- Others
- Research
Segmentation by End-user
- Hospitals
- Diagnostic Imaging Centers
- Academic & Research Centers
- Others
Segmentation by Geography
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Netherlands
- APAC
- China
- Japan
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East & Africa
- Turkey
- Saudi Arabia
- South Africa
- UAE
EXHIBIT 1 MARKET SIZE CALCULATION APPROACH 2023
EXHIBIT 2 GLOBAL MULTIMODAL IMAGING MARKET BY GEOGRAPHY: MARKET SHARE 2023 & 2029 (%)
EXHIBIT 3 GLOBAL MULTIMODAL IMAGING MARKET BY TECHNOLOGY: MARKET SHARE 2023 & 2029 (%)
EXHIBIT 4 GLOBAL MULTIMODAL IMAGING MARKET BY APPLICATION: MARKET SHARE 2023 & 2029 (%)
EXHIBIT 5 GLOBAL MULTIMODAL IMAGING MARKET BY END-USER: MARKET SHARE 2023 & 2029 (%)
EXHIBIT 6 IMPACT OF GROWING ADOPTION OF AI & ANALYTICS IN DIAGNOSTIC IMAGING
EXHIBIT 7 IMPACT OF MULTIMODAL MOLECULAR IMAGING IN DRUG DISCOVERY AND DEVELOPMENT
EXHIBIT 8 APPLICATIONS OF MULTIMODAL IMAGING ACROSS THE STAGES OF DRUG DISCOVERY & DEVELOPMENT
EXHIBIT 9 IMPACT OF AVAILABILITY OF REIMBURSEMENT AND INSURANCE COVERAGE FOR SCANS
EXHIBIT 10 IMPACT OF GROWING GERIATRIC POPULATION AND SUBSEQUENT RISE IN CHRONIC CONDITIONS
EXHIBIT 11 IMPACT OF TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS IMAGING MODALITIES
EXHIBIT 12 IMPACT OF RECENT DEVELOPMENTS & PARTNERSHIPS IN MULTIMODAL IMAGING INDUSTRY
EXHIBIT 13 IMPACT OF NON-INVASIVE IMAGING FUELING GROWTH IN NEUROSCIENCE & ONCOLOGY APPLICATION
EXHIBIT 14 IMPACT OF HIGH OPERATING COST OF IMAGING SYSTEMS
EXHIBIT 15 IMPACT OF GROWING PREFERENCE FOR REFURBISHED EQUIPMENT
EXHIBIT 16 IMPACT OF LACK OF SKILLED PROFESSIONALS
EXHIBIT 17 GLOBAL MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 18 FIVE FORCES ANALYSIS 2023
EXHIBIT 19 INCREMENTAL GROWTH BY TECHNOLOGY 2023 & 2029
EXHIBIT 20 GLOBAL MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023-2029: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 21 GLOBAL MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023-2029: ABSOLUTE GROWTH (%)
EXHIBIT 22 GLOBAL PET/CT MULTIMODAL IMAGING MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 23 GLOBAL PET/CT MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 24 GLOBAL PET/MR MULTIMODAL IMAGING MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 25 GLOBAL PET/MR MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 26 GLOBAL SPECT/CT MULTIMODAL IMAGING MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 27 GLOBAL SPECT/CT MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 28 GLOBAL OCT/FMT MULTIMODAL IMAGING MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 29 GLOBAL OCT/FMT MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 30 GLOBAL OTHERS MULTIMODAL IMAGING MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 31 GLOBAL OTHERS MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 32 INCREMENTAL GROWTH BY APPLICATION 2023 & 2029
EXHIBIT 33 GLOBAL MULTIMODAL IMAGING MARKET BY APPLICATION 2023-2029: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 34 GLOBAL MULTIMODAL IMAGING MARKET BY APPLICATION 2023-2029: ABSOLUTE GROWTH (%)
EXHIBIT 35 GLOBAL DIAGNOSTIC & CLINICAL MULTIMODAL IMAGING MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 36 GLOBAL BRAIN & NEUROLOGY MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 37 GLOBAL ONCOLOGY MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 38 GLOBAL CARDIOLOGY MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 39 GLOBAL OPHTHALMOLOGY MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 40 GLOBAL OTHERS MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 41 GLOBAL DIAGNOSTIC & CLINICAL MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 42 GLOBAL RESEARCH MULTIMODAL IMAGING MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 43 GLOBAL RESEARCH MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 44 INCREMENTAL GROWTH BY END-USER 2023 & 2029
EXHIBIT 45 GLOBAL MULTIMODAL IMAGING MARKET BY END-USER 2023-2029: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 46 GLOBAL MULTIMODAL IMAGING MARKET BY END-USER 2023-2029: ABSOLUTE GROWTH (%)
EXHIBIT 47 GLOBAL HOSPITALS MULTIMODAL IMAGING MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL HOSPITALS MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 49 GLOBAL DIAGNOSTIC CENTERS MULTIMODAL IMAGING MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 50 GLOBAL DIAGNOSTIC CENTERS MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 51 GLOBAL ACADEMIC & RESEARCH CENTERS MULTIMODAL IMAGING MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 52 GLOBAL ACADEMIC & RESEARCH CENTERS MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 53 GLOBAL OTHERS MULTIMODAL IMAGING MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 54 GLOBAL OTHERS MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 55 INCREMENTAL GROWTH BY GEOGRAPHY 2023 & 2029
EXHIBIT 56 GLOBAL MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023-2029: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 57 GLOBAL MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023-2029: ABSOLUTE GROWTH (%)
EXHIBIT 58 NORTH AMERICA MULTIMODAL IMAGING MARKET: MAJOR COUNTRIES BY REVENUE IN 2023 ($ MILLION)
EXHIBIT 59 NORTH AMERICA MULTIMODAL IMAGING MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 60 NORTH AMERICA MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 61 INCREMENTAL GROWTH IN NORTH AMERICA 2023 & 2029
EXHIBIT 62 US MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 63 CANADA MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 64 EUROPE MULTIMODAL IMAGING MARKET: MAJOR COUNTRIES BY REVENUE IN 2023 ($ MILLION)
EXHIBIT 65 EUROPE MULTIMODAL IMAGING MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 66 EUROPE MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 67 INCREMENTAL GROWTH IN EUROPE 2023 & 2029
EXHIBIT 68 GERMANY MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 69 FRANCE MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 70 UK MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 71 ITALY MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 72 SPAIN MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 73 RUSSIA MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 74 NETHERLANDS MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 75 APAC MULTIMODAL IMAGING MARKET: MAJOR COUNTRIES BY REVENUE IN 2023 ($ MILLION)
EXHIBIT 76 APAC MULTIMODAL IMAGING MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 77 APAC MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 78 INCREMENTAL GROWTH IN APAC 2023 & 2029
EXHIBIT 79 CHINA MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 80 JAPAN MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 81 INDIA MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 82 SOUTH KOREA MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 83 AUSTRALIA MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 84 LATIN AMERICA MULTIMODAL IMAGING MARKET: MAJOR COUNTRIES BY REVENUE IN 2023 ($ MILLION)
EXHIBIT 85 LATIN AMERICA MULTIMODAL IMAGING MARKET 2023–2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 86 LATIN AMERICA MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 87 INCREMENTAL GROWTH IN LATIN AMERICA 2023 & 2029
EXHIBIT 88 BRAZIL MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 89 MEXICO MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 90 ARGENTINA MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 91 COLOMBIA MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 92 MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET: MAJOR COUNTRIES BY REVENUE IN 2023 ($ MILLION)
EXHIBIT 93 MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET 2023–2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 94 MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 95 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2023 & 2029
EXHIBIT 96 TURKEY MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 97 SAUDI ARABIA MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 98 SOUTH AFRICA MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 99 UAE MULTIMODAL IMAGING MARKET 2020–2029 ($ MILLION)
EXHIBIT 100 VENDORS OFFERING MULTIMODAL IMAGING PRODUCTS: MARKET DOMINANCE ANALYSIS
EXHIBIT 101 VENDORS OFFERING COMMERCIAL MULTIMODAL IMAGING PRODUCTS: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 102 KEY CAVEATS
LIST OF TABLES
TABLE 1 GLOBAL PET/CT MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 2 GLOBAL PET/CT MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 3 GLOBAL PET/MR MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 4 GLOBAL PET/MR MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 5 GLOBAL SPECT/CT MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 6 GLOBAL SPECT/CT MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 7 GLOBAL OCT/FMT MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 8 GLOBAL OCT/FMT MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 9 GLOBAL OTHERS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 10 GLOBAL OTHERS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 11 GLOBAL DIAGNOSTIC & CLINICAL MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 12 GLOBAL DIAGNOSTIC & CLINICAL MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 13 GLOBAL RESEARCH MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 14 GLOBAL RESEARCH MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 15 GLOBAL HOSPITALS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 16 GLOBAL HOSPITALS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 17 GLOBAL DIAGNOSTIC CENTERS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 18 GLOBAL DIAGNOSTIC CENTERS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 19 GLOBAL ACADEMIC & RESEARCH CENTERS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 20 GLOBAL ACADEMIC & RESEARCH CENTERS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 21 GLOBAL OTHERS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 22 GLOBAL OTHERS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 23 NORTH AMERICA MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 ($ MILLION)
TABLE 24 NORTH AMERICA MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 (%)
TABLE 25 NORTH AMERICA MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 26 NORTH AMERICA MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 (%)
TABLE 27 NORTH AMERICA MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 28 NORTH AMERICA MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 (%)
TABLE 29 EUROPE MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 ($ MILLION)
TABLE 30 EUROPE MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 (%)
TABLE 31 EUROPE MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 32 EUROPE MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 (%)
TABLE 33 EUROPE MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 34 EUROPE MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 (%)
TABLE 35 APAC MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 ($ MILLION)
TABLE 36 APAC MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 (%)
TABLE 37 APAC MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 38 APAC MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 (%)
TABLE 39 APAC MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 40 APAC MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 (%)
TABLE 41 LATIN AMERICA MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 ($ MILLION)
TABLE 42 LATIN AMERICA MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 (%)
TABLE 43 LATIN AMERICA MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 44 LATIN AMERICA MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 (%)
TABLE 45 LATIN AMERICA MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 46 LATIN AMERICA MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 (%)
TABLE 47 MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 ($ MILLION)
TABLE 48 MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 (%)
TABLE 49 MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 50 MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 (%)
TABLE 51 MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 52 MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 (%)
TABLE 53 CANON MEDICAL SYSTEMS: MAJOR PRODUCT OFFERINGS
TABLE 54 GE HEALTHCARE: MAJOR PRODUCT OFFERINGS
TABLE 55 KONINKLIJKE PHILIPS: MAJOR PRODUCT OFFERINGS
TABLE 56 SHIMADZU CORPORATION: MAJOR PRODUCT OFFERINGS
TABLE 57 SIEMENS HEALTHINEERS: MAJOR PRODUCT OFFERINGS
TABLE 58 BRUKER: MAJOR PRODUCT OFFERINGS
TABLE 59 MEDISO: MAJOR PRODUCT OFFERINGS
TABLE 60 MILABS B.V.: MAJOR PRODUCT OFFERINGS
TABLE 61 MINFOUND MEDICAL SYSTEMS: MAJOR PRODUCT OFFERINGS
TABLE 62 MR SOLUTION: MAJOR PRODUCT OFFERINGS
TABLE 63 SHANGHAI UNITED IMAGING HEALTHCARE: MAJOR PRODUCT OFFERINGS
TABLE 64 SOFIE: MAJOR PRODUCT OFFERINGS
TABLE 65 SPECTRUM DYNAMICS MEDICAL: MAJOR PRODUCT OFFERINGS
TABLE 66 TOPCON: MAJOR PRODUCT OFFERINGS
TABLE 67 GLOBAL MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 ($ MILLION)
TABLE 68 GLOBAL MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 (%)
TABLE 69 NORTH AMERICA MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 ($ MILLION)
TABLE 70 NORTH AMERICA MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 (%)
TABLE 71 EUROPE MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 ($ MILLION)
TABLE 72 EUROPE MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 (%)
TABLE 73 APAC MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 ($ MILLION)
TABLE 74 APAC MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 (%)
TABLE 75 LATIN AMERICA MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 ($ MILLION)
TABLE 76 LATIN AMERICA MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 (%)
TABLE 77 MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 ($ MILLION)
TABLE 78 MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET BY TECHNOLOGY 2023−2029 (%)
TABLE 79 GLOBAL MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 80 GLOBAL MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 (%)
TABLE 81 NORTH AMERICA MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 82 NORTH AMERICA MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 (%)
TABLE 83 EUROPE MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 84 EUROPE MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 (%)
TABLE 85 APAC MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 86 APAC MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 (%)
TABLE 87 LATIN AMERICA MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 88 LATIN AMERICA MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 (%)
TABLE 89 MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 90 MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET BY APPLICATION 2023−2029 (%)
TABLE 91 GLOBAL MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 92 GLOBAL MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 (%)
TABLE 93 NORTH AMERICA MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 94 NORTH AMERICA MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 (%)
TABLE 95 EUROPE MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 96 EUROPE MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 (%)
TABLE 97 APAC MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 98 APAC MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 (%)
TABLE 99 LATIN AMERICA MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 100 LATIN AMERICA MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 (%)
TABLE 101 MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 102 MIDDLE EAST & AFRICA MULTIMODAL IMAGING MARKET BY END-USER 2023−2029 (%)
TABLE 103 GLOBAL MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 104 GLOBAL MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 105 GLOBAL PET/CT MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 106 GLOBAL PET/CT MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 107 GLOBAL PET/MR MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 108 GLOBAL PET/MR MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 109 GLOBAL SPECT/CT MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 110 GLOBAL SPECT/CT MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 111 GLOBAL OCT/FMT MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 112 GLOBAL OCT/FMT MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 113 GLOBAL OTHERS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 114 GLOBAL OTHERS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 115 GLOBAL DIAGNOSTIC & CLINICAL MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 116 GLOBAL DIAGNOSTIC & CLINICAL MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 117 GLOBAL RESEARCH MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 118 GLOBAL RESEARCH MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 119 GLOBAL HOSPITALS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 120 GLOBAL HOSPITALS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 121 GLOBAL DIAGNOSTIC CENTER MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 122 GLOBAL DIAGNOSTIC CENTER MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 123 GLOBAL ACADEMIC & RESEARCH CENTER MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 124 GLOBAL ACADEMIC & RESEARCH CENTER MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 125 GLOBAL OTHERS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 126 GLOBAL OTHERS MULTIMODAL IMAGING MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 127 CURRENCY CONVERSION 2016−2023
1. SCOPE & COVERAGE
1.1. MARKET DEFINITION
1.1.1. INCLUSIONS
1.1.2. EXCLUSIONS
1.1.3. MARKET ESTIMATION CAVEATS
1.2. MARKET SEGMENTATION COVERAGE
1.2.1. MARKET BY TECHNOLOGY
1.2.2. MARKET BY APPLICATION
1.2.3. MARKET BY END-USER
1.2.4. REGIONS & COUNTRIES COVERED
1.3. MARKET DERIVATION
1.3.1. BASE YEAR
2. PREMIUM INSIGHTS
2.1. OPPORTUNITY POCKETS
2.2. OVERVIEW
2.2.1. GEOGRAPHY INSIGHTS
2.2.2. TECHNOLOGY INSIGHTS
2.2.3. APPLICATION INSIGHTS
2.2.4. END-USER INSIGHTS
3. MARKET AT A GLANCE
4. INTRODUCTION
4.1. OVERVIEW
5. MARKET OPPORTUNITIES & TRENDS
5.1. GROWING ADOPTION OF AI & ANALYTICS IN DIAGNOSTIC IMAGING
5.2. MULTIMODAL MOLECULAR IMAGING IN DRUG DISCOVERY AND DEVELOPMENT
5.3. AVAILABILITY OF REIMBURSEMENT AND INSURANCE COVERAGE FOR SCANS
6. MARKET GROWTH ENABLERS
6.1. GROWING GERIATRIC POPULATION AND SUBSEQUENT RISE IN CHRONIC CONDITIONS
6.2. TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS IMAGING MODALITIES
6.3. RECENT DEVELOPMENTS & PARTNERSHIPS IN MULTIMODAL IMAGING INDUSTRY
6.4. NON-INVASIVE IMAGING FUELING GROWTH IN NEUROSCIENCE & ONCOLOGY APPLICATION
7. MARKET RESTRAINTS
7.1. HIGH OPERATING COST OF IMAGING SYSTEMS
7.2. GROWING PREFERENCE FOR REFURBISHED EQUIPMENT
7.3. LACK OF SKILLED PROFESSIONALS
8. MARKET LANDSCAPE
8.1. MARKET OVERVIEW
8.2. MARKET SIZE & FORECAST
8.3. FIVE FORCES ANALYSIS
8.3.1. THREAT OF NEW ENTRANTS
8.3.2. BARGAINING POWER OF SUPPLIERS
8.3.3. BARGAINING POWER OF BUYERS
8.3.4. THREAT OF SUBSTITUTES
8.3.5. COMPETITIVE RIVALRY
9. TECHNOLOGY
9.1. MARKET SNAPSHOT & GROWTH ENGINE
9.2. MARKET OVERVIEW
9.3. PET/CT
9.3.1. MARKET OVERVIEW
9.3.2. MARKET SIZE & FORECAST
9.3.3. PET/CT MARKET BY GEOGRAPHY
9.4. PET/MR
9.4.1. MARKET OVERVIEW
9.4.2. MARKET SIZE & FORECAST
9.4.3. PET/MR MARKET BY GEOGRAPHY
9.5. SPECT/CT
9.5.1. MARKET OVERVIEW
9.5.2. MARKET SIZE & FORECAST
9.5.3. SPECT/CT MARKET BY GEOGRAPHY
9.6. OCT/FMT
9.6.1. MARKET OVERVIEW
9.6.2. MARKET SIZE & FORECAST
9.6.3. OCT/FMT MARKET BY GEOGRAPHY
9.7. OTHERS
9.7.1. MARKET OVERVIEW
9.7.2. MARKET SIZE & FORECAST
9.7.3. OTHERS MARKET BY GEOGRAPHY
10. APPLICATION
10.1. MARKET SNAPSHOT & GROWTH ENGINE
10.2. MARKET OVERVIEW
10.3. DIAGNOSTIC & CLINICAL
10.3.1. MARKET OVERVIEW
10.3.2. MARKET SIZE & FORECAST
10.3.3. DIAGNOSTIC & CLINICAL MARKET BY GEOGRAPHY
10.4. RESEARCH
10.4.1. MARKET OVERVIEW
10.4.2. MARKET SIZE & FORECAST
10.4.3. RESEARCH MARKET BY GEOGRAPHY
11. END-USER
11.1. MARKET SNAPSHOT & GROWTH ENGINE
11.2. MARKET OVERVIEW
11.3. HOSPITALS
11.3.1. MARKET OVERVIEW
11.3.2. MARKET SIZE & FORECAST
11.3.3. HOSPITALS MARKET BY GEOGRAPHY
11.4. DIAGNOSTIC IMAGING CENTERS
11.4.1. MARKET OVERVIEW
11.4.2. MARKET SIZE & FORECAST
11.4.3. DIAGNOSTIC IMAGING CENTERS MARKET BY GEOGRAPHY
11.5. ACADEMIC & RESEARCH CENTERS
11.5.1. MARKET OVERVIEW
11.5.2. MARKET SIZE & FORECAST
11.5.3. ACADEMIC & RESEARCH CENTERS MARKET BY GEOGRAPHY
11.6. OTHERS
11.6.1. MARKET OVERVIEW
11.6.2. MARKET SIZE & FORECAST
11.6.3. OTHERS MARKET BY GEOGRAPHY
12. GEOGRAPHY
12.1. MARKET SNAPSHOT & GROWTH ENGINE
12.2. GEOGRAPHIC OVERVIEW
13. NORTH AMERICA
13.1. MARKET OVERVIEW
13.2. MARKET SIZE & FORECAST
13.2.1. NORTH AMERICA MARKET BY TECHNOLOGY
13.2.2. NORTH AMERICA MARKET BY APPLICATION
13.2.3. NORTH AMERICA MARKET BY END-USER
13.3. KEY COUNTRIES
13.3.1. US: MARKET SIZE & FORECAST
13.3.2. CANADA: MARKET SIZE & FORECAST
14. EUROPE
14.1. MARKET OVERVIEW
14.2. MARKET SIZE & FORECAST
14.2.1. EUROPE MARKET BY TECHNOLOGY
14.2.2. EUROPE MARKET BY APPLICATION
14.2.3. EUROPE MARKET BY END-USER
14.3. KEY COUNTRIES
14.3.1. GERMANY: MARKET SIZE & FORECAST
14.3.2. FRANCE: MARKET SIZE & FORECAST
14.3.3. UK: MARKET SIZE & FORECAST
14.3.4. ITALY: MARKET SIZE & FORECAST
14.3.5. SPAIN: MARKET SIZE & FORECAST
14.3.6. RUSSIA: MARKET SIZE & FORECAST
14.3.7. NETHERLANDS: MARKET SIZE & FORECAST
15. APAC
15.1. MARKET OVERVIEW
15.2. MARKET SIZE & FORECAST
15.2.1. APAC MARKET BY TECHNOLOGY
15.2.2. APAC MARKET BY APPLICATION
15.2.3. APAC MARKET BY END-USER
15.3. KEY COUNTRIES
15.3.1. CHINA: MARKET SIZE & FORECAST
15.3.2. JAPAN: MARKET SIZE & FORECAST
15.3.3. INDIA: MARKET SIZE & FORECAST
15.3.4. SOUTH KOREA: MARKET SIZE & FORECAST
15.3.5. AUSTRALIA: MARKET SIZE & FORECAST
16. LATIN AMERICA
16.1. MARKET OVERVIEW
16.2. MARKET SIZE & FORECAST
16.2.1. LATIN AMERICA MARKET BY TECHNOLOGY
16.2.2. LATIN AMERICA MARKET BY APPLICATION
16.2.3. LATIN AMERICA MARKET BY END-USER
16.3. KEY COUNTRIES
16.3.1. BRAZIL: MARKET SIZE & FORECAST
16.3.2. MEXICO: MARKET SIZE & FORECAST
16.3.3. ARGENTINA: MARKET SIZE & FORECAST
16.3.4. COLOMBIA: MARKET SIZE & FORECAST
17. MIDDLE EAST & AFRICA
17.1. MARKET OVERVIEW
17.2. MARKET SIZE & FORECAST
17.2.1. MIDDLE EAST & AFRICA MARKET BY TECHNOLOGY
17.2.2. MIDDLE EAST & AFRICA MARKET BY APPLICATION
17.2.3. MIDDLE EAST & AFRICA MARKET BY END-USER
17.3. KEY COUNTRIES
17.3.1. TURKEY: MARKET SIZE & FORECAST
17.3.2. SAUDI ARABIA: MARKET SIZE & FORECAST
17.3.3. SOUTH AFRICA: MARKET SIZE & FORECAST
17.3.4. UAE: MARKET SIZE & FORECAST
18. COMPETITIVE LANDSCAPE
18.1. COMPETITION OVERVIEW
18.2. MARKET SHARE ANALYSIS
18.2.1. CANON MEDICAL SYSTEMS
18.2.2. GE HEALTHCARE
18.2.3. KONINKLIJKE PHILIPS
18.2.4. SHIMADZU CORPORATION
18.2.5. SIEMENS HEALTHINEERS
19. KEY COMPANY PROFILES
19.1. CANON MEDICAL SYSTEMS
19.1.1. BUSINESS OVERVIEW
19.1.2. PRODUCT OFFERINGS
19.1.3. KEY STRATEGIES
19.1.4. KEY STRENGTHS
19.1.5. KEY OPPORTUNITIES
19.2. GE HEALTHCARE
19.2.1. BUSINESS OVERVIEW
19.2.2. PRODUCT OFFERINGS
19.2.3. KEY STRATEGIES
19.2.4. KEY STRENGTHS
19.2.5. KEY OPPORTUNITIES
19.3. KONINKLIJKE PHILIPS
19.3.1. BUSINESS OVERVIEW
19.3.2. PRODUCT OFFERINGS
19.3.3. KEY STRATEGIES
19.3.4. KEY STRENGTHS
19.3.5. KEY OPPORTUNITIES
19.4. SHIMADZU CORPORATION
19.4.1. BUSINESS OVERVIEW
19.4.2. PRODUCT OFFERINGS
19.4.3. KEY STRATEGIES
19.4.4. KEY STRENGTHS
19.4.5. KEY OPPORTUNITIES
19.5. SIEMENS HEALTHINEERS
19.5.1. BUSINESS OVERVIEW
19.5.2. PRODUCT OFFERINGS
19.5.3. KEY STRATEGIES
19.5.4. KEY STRENGTHS
19.5.5. KEY OPPORTUNITIES
20. OTHER PROMINENT VENDORS
20.1. BRUKER
20.1.1. BUSINESS OVERVIEW
20.1.2. PRODUCT OFFERINGS
20.2. MEDISO
20.2.1. BUSINESS OVERVIEW
20.2.2. PRODUCT OFFERINGS
20.3. MILABS B.V.
20.3.1. BUSINESS OVERVIEW
20.3.2. PRODUCT OFFERINGS
20.4. MINFOUND MEDICAL SYSTEMS
20.4.1. BUSINESS OVERVIEW
20.4.2. PRODUCT OFFERINGS
20.5. MR SOLUTION
20.5.1. BUSINESS OVERVIEW
20.5.2. PRODUCT OFFERINGS
20.6. SHANGHAI UNITED IMAGING HEALTHCARE
20.6.1. BUSINESS OVERVIEW
20.6.2. PRODUCT OFFERINGS
20.7. SOFIE
20.7.1. BUSINESS OVERVIEW
20.7.2. PRODUCT OFFERINGS
20.8. SPECTRUM DYNAMICS MEDICAL
20.8.1. BUSINESS OVERVIEW
20.8.2. PRODUCT OFFERINGS
20.9. TOPCON
20.9.1. BUSINESS OVERVIEW
20.9.2. PRODUCT OFFERINGS
21. REPORT SUMMARY
21.1. KEY TAKEAWAYS
21.2. STRATEGIC RECOMMENDATIONS
22. QUANTITATIVE SUMMARY
22.1. MARKET BY TECHNOLOGY
22.1.1. NORTH AMERICA MARKET BY TECHNOLOGY
22.1.2. EUROPE MARKET BY TECHNOLOGY
22.1.3. APAC MARKET BY TECHNOLOGY
22.1.4. LATIN AMERICA MARKET BY TECHNOLOGY
22.1.5. MIDDLE EAST & AFRICA MARKET BY TECHNOLOGY
22.2. MARKET BY APPLICATION
22.2.1. NORTH AMERICA MARKET BY APPLICATION
22.2.2. EUROPE MARKET BY APPLICATION
22.2.3. APAC MARKET BY APPLICATION
22.2.4. LATIN AMERICA MARKET BY APPLICATION
22.2.5. MIDDLE EAST & AFRICA MARKET BY APPLICATION
22.3. MARKET BY END-USER
22.3.1. NORTH AMERICA MARKET BY END-USER
22.3.2. EUROPE MARKET BY END-USER
22.3.3. APAC MARKET BY END-USER
22.3.4. LATIN AMERICA MARKET BY END-USER
22.3.5. MIDDLE EAST & AFRICA MARKET BY END-USER
22.4. MARKET BY GEOGRAPHY
22.4.1. PET/CT MARKET BY GEOGRAPHY
22.4.2. PET/MR MARKET BY GEOGRAPHY
22.4.3. SPECT/CT MARKET BY GEOGRAPHY
22.4.4. OCT/FMT MARKET BY GEOGRAPHY
22.4.5. OTHERS MARKET BY GEOGRAPHY
22.4.6. DIAGNOSTIC & CLINICAL MARKET BY GEOGRAPHY
22.4.7. RESEARCH MARKET BY GEOGRAPHY
22.4.8. HOSPITALS MARKET BY GEOGRAPHY
22.4.9. DIAGNOSTIC IMAGING CENTERS MARKET BY GEOGRAPHY
22.4.10. ACADEMIC & RESEARCH CENTERS MARKET BY GEOGRAPHY
22.4.11. OTHERS MARKET BY GEOGRAPHY
23. APPENDIX
23.1. RESEARCH METHODOLOGY
23.2. RESEARCH PROCESS
23.3. REPORT ASSUMPTIONS & CAVEATS
23.3.1. KEY CAVEATS
23.3.2. CURRENCY CONVERSION
23.4. ABBREVIATIONS
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
How big is the global multimodal imaging market?
What is the growth rate of the global multimodal imaging market?
Which region dominates the global multimodal imaging market share?
What are the significant trends in the global multimodal imaging market?
Who are the key players in the global multimodal imaging market?